Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

PLX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Protalix BioTherapeutics, Inc.AMEX: PLX

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to 54.3%

Net margin was 54.3% in Q1 FY2026, up 90.1 pp from a year earlier. On a trailing-twelve-month basis it was 20.1%, up 13.5 pp year over year. Over 3 fiscal years it widened by 18.8 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 1 analysts of 24.4% for the fiscal year ending Dec 2026, up from -12.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
54.3%+114.6 pp QoQ
Last fiscal yearDec 2025
-12.5%-18.0 pp YoY
LTMMar 2026
20.1%+13.5 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+90.1 pp-7.5 pp-97.6 pp
1 year-18.0 pp+36.9 pp+54.9 pp
3 years+18.8 pp+19.7 pp+0.9 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-12.5%
Year-over-year change
-18.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How PLX compares with its peers on the latest reported figures

  • PLX's LTM Mar 2026 net margin of 20.1% is the highest of the 3 companies compared; the peer median is -43.8%.
  • Its year-over-year change of +13.5 pp is the highest of 3, against a peer median of +4.9 pp.
  • Over three fiscal years its change of +18.8 pp compares with a peer median of +51.7 pp.
PLX Competitors Peer median
Net Margin for PLX and competitors
Company Period LTM level YoY 3-year change
PLXProtalix BioTherapeutics, Inc.LTM Mar 202620.1% +13.5 pp+18.8 pp
PHARPharming Group N.V.LTM Mar 20263.3% +7.7 pp-5.9 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-91.0% +2.0 pp+109.3 pp
PLYXPolaryx Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding PLX) -43.8%+4.9 pp+51.7 pp

Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.35M47.64M65.49M53.4M52.74M
Cost of Revenue16.35M19.59M22.98M24.32M27.51M
Gross Profit22M28.05M42.51M29.08M25.24M
Gross Margin57.4%58.9%64.9%54.5%47.8%
Research & Development29.73M29.35M17.09M12.97M19.05M
Selling, General & Admin12.73M11.71M14.96M12.19M11.68M
Operating Expenses42.46M41.06M32.05M25.16M30.74M
Depreciation & Amortization1.12M1.09M1.19M1.3M1.47M
EBITDA(18.94M)(10.78M)12.94M6.52M(2.95M)
EBITDA Margin-49.4%-22.6%19.8%12.2%-5.6%
Operating Income(20.46M)(13.01M)10.46M3.92M(5.5M)
Operating Margin-53.4%-27.3%16.0%7.3%-10.4%
Interest Income401K1.15M1.29M1.3M1.08M
Interest Expense7.52M2.53M3.18M1.06M1.19M
Other Income / Expenses(7.12M)(1.38M)(1.89M)237K(108K)
Income Before Tax(27.58M)(14.4M)8.57M4.15M(5.61M)
Pre-Tax Margin-71.9%-30.2%13.1%7.8%-10.6%
Income Tax Expense0530K254K1.22M996K
Net Income(27.58M)(14.93M)8.31M2.93M(6.6M)
Net Margin-71.9%-31.3%12.7%5.5%-12.5%
EPS (Basic)(0.62)(0.31)0.120.04(0.08)
EPS (Diluted)(0.62)(0.31)0.100.04(0.08)
Weighted Avg Shares44.14M48.47M67.51M72.53M78.55M
Weighted Avg Shares (Diluted)44.14M48.47M82.42M81.06M78.55M

Protalix BioTherapeutics, Inc.

AMEX:PLX

Intrinsic Alpha fair value

Locked

Current Price

$3.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.